We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

246 hedge funds and large institutions have $4.83B invested in Pacific Biosciences in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 97 increasing their positions, 77 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 77

7.93% more ownership

Funds ownership: 87.04% → 94.96% (+7.9%)

6% less funds holding

Funds holding: 262 → 246 (-16)

20% less capital invested

Capital invested by funds: $6.03B → $4.83B (-$1.2B)

33% less call options, than puts

Call options by funds: $31.8M | Put options by funds: $47.5M

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

36% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 39

Holders
246
Holders Change
-16
Holders Change %
-6.11%
% of All Funds
4.31%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.07%
New
25
Increased
97
Reduced
77
Closed
39
Calls
$31.8M
Puts
$47.5M
Net Calls
-$15.6M
Net Calls Change
-$21.3M

Top Buyers

Rank Fund Capital Flow
1
William Blair Investment Management
William Blair Investment Management
Illinois
+$121M
2
CC
Casdin Capital
New York
+$88.6M
3
Capital International Investors
Capital International Investors
California
+$77.5M
4
BBA
Baker Bros. Advisors
New York
+$66.5M
5
AIM
ARK Investment Management
Florida
+$66.4M

Top Sellers

Rank Fund Capital Flow
1
SM
SB Management
United Arab Emirates
-$50.5M
2
Viking Global Investors
Viking Global Investors
Connecticut
-$44.5M
3
ITP
Iron Triangle Partners
Connecticut
-$34.1M
4
Two Sigma Investments
Two Sigma Investments
New York
-$17.5M
5
Renaissance Technologies
Renaissance Technologies
New York
-$16.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
JPG
251
Jordan Park Group
California
– -$1.17M -33,386 Closed
OMC
252
Old Mission Capital
Illinois
– -$1.15M -32,966 Closed
BAM
253
Blueshift Asset Management
New Jersey
– -$955K -27,318 Closed
SC
254
Shay Capital
New York
– -$699K -20,000 Closed
CM
255
Caption Management
Oklahoma
– -$584K -19,700 Closed
DCM
256
Dupont Capital Management
Delaware
– -$615K -17,581 Closed
QSS
257
Quantitative Systematic Strategies
Florida
– -$567K -16,226 Closed
KOC
258
Koss-Olinger Consulting
Florida
– -$525K -15,000 Closed
OC
259
Oppenheimer & Co
New York
– -$461K -13,171 Closed
Man Group
260
Man Group
United Kingdom
– -$444K -12,711 Closed
CLOS
261
Compagnie Lombard Odier SCmA
Switzerland
– -$370K -12,500 Closed
CCIA
262
Campbell & Co Investment Adviser
Maryland
– -$350K -10,000 Closed
SM
263
SG3 Management
Puerto Rico
– -$350K -10,000 Closed
CC
264
Centiva Capital
New York
– -$305K -8,736 Closed
FCH
265
Freestone Capital Holdings
Washington
– -$269K -7,700 Closed
RJFSA
266
Raymond James Financial Services Advisors
Florida
– -$264K -7,556 Closed
SFS
267
Strategic Financial Services
New York
– -$262K -7,500 Closed
DLG
268
Daniel L. Goodwin
– -$245K -7,000 Closed
CFG
269
Citizens Financial Group
Rhode Island
– -$219K -6,274 Closed
SC
270
Scholtz & Company
Connecticut
– -$216K -6,165 Closed
Walleye Capital
271
Walleye Capital
New York
– -$213 -6,100 Closed
HTC
272
Hershey Trust Company
Pennsylvania
– -$184K -5,258 Closed
NICM
273
Neo Ivy Capital Management
New York
– -$180K -5,143 Closed
Rockefeller Capital Management
274
Rockefeller Capital Management
New York
– -$153K -4,413 Closed
Pacer Advisors
275
Pacer Advisors
Pennsylvania
– -$138K -3,933 Closed
8 9 10
11
12

PACB Hedge Fund Activity: Q3 2021 in Review

246 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2021, worth a combined $4.83B — down 20% from $6.03B a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of PACB and 25 opened new positions — a net loss of 14 holders — while 77 trimmed existing stakes and 97 added.

The largest buyer was William Blair Investment Management, opening a new position worth an estimated $121M. The largest seller was SB Management, cutting an estimated $50.5M.

  • 246 institutional investors held Pacific Biosciences (PACB) as of Q3 2021, down from 262 in Q2 2021.
  • Funds reported $4.83B of Pacific Biosciences stock for Q3 2021, down 20% quarter-over-quarter.
  • 25 funds opened new Pacific Biosciences positions in Q3 2021 and 39 closed out, a net change of -14 holders.
  • The largest Pacific Biosciences buyer in Q3 2021 was William Blair Investment Management, an estimated $121M added.
  • The largest Pacific Biosciences seller in Q3 2021 was SB Management, an estimated $50.5M sold.

Based on aggregated 13F filings for Q3 2021.